Protocol No.: GO44145

SKYGLO: A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Safety and Efficacy of Glofitimab (RO7082859) in Combination with Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma
Principal Investigator
Safi, Salah Ud Din
Phase
III
Age Group
Adult
Applicable Disease Site
Lymphoma
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Kenna DeLancey
Study Coordinator

View on ClinicalTrials.gov